Cardio3 BioSciences Receives Authorization to Begin World’s First Phase III Clinical Trial in Regenerative Medicine for Heart Failure

Cardio3 BioSciences Receives Authorization to Begin World’s First Phase III Clinical Trial in Regenerative Medicine for Heart Failure

Zhang et al. - 2012 - An NKp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo

Zhang et al. - 2012 - An NKp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo

Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at European Society of Cardiology 2012 Heart Failure Congress

Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at European Society of Cardiology 2012 Heart Failure Congress

Spear et al. - 2012 - Chimeric Antigen Receptor T Cells Shape Myeloid Cell Function within the Tumor Microenvironment through IFN-γ and GM-CSF (only in english)

Spear et al. - 2012 - Chimeric Antigen Receptor T Cells Shape Myeloid Cell Function within the Tumor Microenvironment through IFN-γ and GM-CSF (only in english)

Cardio3 BioSciences Announces CE Marking for its C-Cath® Injection Catheter

Cardio3 BioSciences Announces CE Marking for its C-Cath® Injection Catheter

Cardio3 BioSciences Granted GMP Certification

Cardio3 BioSciences Granted GMP Certification

Cardio3 BioSciences Receives ISO-13485 Certification

Cardio3 BioSciences Receives ISO-13485 Certification

Cardio3 BioSciences Secures Additional €3.1 million in Non-dilutive Funding from the Walloon Region and the European Commission

Cardio3 BioSciences Secures Additional €3.1 million in Non-dilutive Funding from the Walloon Region and the European Commission